Uncategorized
Fluocinolone acetonide implant reduces treatment burden in DME
BALTIMORE — An intravitreal injection of a fluocinolone acetonide implant decreases the treatment burden of diabetic macular edema by increasing the interval between injections for patients who are unsuccessful with first-line anti-VEGF therapies, according to research presented at the Association for Research in Vision and Ophthalmology annual meeting.The retrospective study included 16 eyes with DME that failed treatment with an initial VEGF inhibitor and were subsequently injected with a fluocinolone acetonide implant.